An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.

Expression of urokinase (uPA) and its receptor (uPAR) is associated with increased tumor-cellinvasion and metastasis in several malignancies including breast cancer. An 8-mer peptide derived from the nonreceptor-binding domain of urokinase (A6) has been shown to have antiangiogenic and proapoptotic effects to block the progression of breast cancer in vivo. In the present study, we evaluated the effects of A6 and the antiestrogen tamoxifen (TAM) alone and in combination on estrogen-receptor-positive Mat B-III rat breast cancer cells in vitro and in vivo. Treatment of Mat B-III cells with A6 and TAM resulted in a dose-dependent decrease in tumor-cell invasion through Matrigel; these effects were more marked when A6 and TAM were tested in combination. In addition, treatment of Mat B-III cells with either A6 or TAM resulted in a significant reduction of vascular endothelial growth factor receptor (flk-1) expression and in transforming growth factor beta activity, effects that were significantly higher after combined treatment with A6 and TAM. For in vivo studies, female Fischer rats were inoculated with Mat B-III cells (1 x 10(6)) into the mammary fat pad. These orthotopic tumors were staged to 30-40 mm(3) in volume and then treatment was initiated with A6 (75 mg/kg/day) and TAM (3 mg/kg/day) alone or in combination. Both A6 and TAM caused a significant reduction in tumor volume; however, these antitumor effects were significantly greater in animals receiving both A6 and TAM, which demonstrated a 75% reduction in tumor growth as compared with control animals. The number of macroscopic tumor foci was significantly reduced in A6-treated animals, whereas TAM failed to exhibit any antimetastatic effects. Histological analysis of primary tumors from different groups showed a decrease in new blood-vessel density and increased tumor-cell death in A6- and TAM-treated animals, and these effects were greater in experimental animals receiving A6 and TAM in combination. Collectively, these studies demonstrate that the addition of novel antiangiogenic/antimetastatic agents like A6 to hormone therapy can enhance the antitumor effects of hormone therapy through increased inhibition of angiogenesis and induction of tumor-cell death.

[1]  B. Weeks,et al.  Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. , 2001, Cancer research.

[2]  H. Höfler,et al.  Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  A. Harris,et al.  Plasminogen activator inhibitor‐1 as a measure of vascular remodelling in breast cancer , 2001, The Journal of pathology.

[4]  S. Soker,et al.  Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. , 2001, The American journal of pathology.

[5]  H. Shimada,et al.  Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. , 2001, Cancer research.

[6]  R. Busse,et al.  Thrombin Activates the Hypoxia-Inducible Factor-1 Signaling Pathway in Vascular Smooth Muscle Cells: Role of the p22phox-Containing NADPH Oxidase , 2001, Circulation research.

[7]  E. Skrzypczak‐Jankun,et al.  Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. , 2001, Oncology reports.

[8]  A. Mazar,et al.  The role of the plasminogen activation system in angiogenesis and metastasis. , 2001, Surgical oncology clinics of North America.

[9]  D. Lawrence,et al.  Inhibition of Angiogenesis in Vivo by Plasminogen Activator Inhibitor-1* , 2001, The Journal of Biological Chemistry.

[10]  S. Jiang,et al.  Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[11]  Nils Brünner,et al.  The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin , 2001, The Journal of cell biology.

[12]  E. Baker,et al.  Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression , 2000, Molecular pathology : MP.

[13]  A. Gown,et al.  A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Mazar,et al.  A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  A. Al-Mehdi,et al.  Urokinase‐derived peptides regulate vascular smooth muscle contraction in vitro and in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  D. Cameron,et al.  Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. , 2000, European journal of cancer.

[17]  S. Tsao,et al.  Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat , 1999, British Journal of Cancer.

[18]  M. Duffy,et al.  Urokinase plasminogen activator: A prognostic marker in multiple types of cancer , 1999, Journal of surgical oncology.

[19]  S. Rabbani,et al.  Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: Role of DNA methylation. , 1999, International journal of cancer.

[20]  J. Verheijen,et al.  Mitogenic Effects of Urokinase on Melanoma Cells Are Independent of High Affinity Binding to the Urokinase Receptor* , 1998, The Journal of Biological Chemistry.

[21]  M. Brizzi,et al.  Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients. , 1998, International journal of oncology.

[22]  A. Mazar,et al.  Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. , 1997, Cancer research.

[23]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[24]  F. Chiaradonna,et al.  Phosphorylation of Human Pro-Urokinase on Ser138/303 Impairs Its Receptor-dependent Ability to Promote Myelomonocytic Adherence and Motility , 1997, The Journal of cell biology.

[25]  K. Preissner,et al.  Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. , 1996, Blood.

[26]  S. Brem,et al.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. , 1995, The Journal of clinical investigation.

[27]  R. Hildenbrand,et al.  Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. , 1995, Pathology, research and practice.

[28]  J. Russo,et al.  The etiopathogenesis of breast cancer prevention. , 1995, Cancer letters.

[29]  S. Ahmed,et al.  A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. , 1994, Journal of immunological methods.

[30]  S. Rabbani,et al.  Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts , 1994, FEBS letters.

[31]  Jeffrey L. Wrana,et al.  TGFβ signals through a heteromeric protein kinase receptor complex , 1992, Cell.

[32]  M. Llinás,et al.  Heparin binding to the urokinase kringle domain. , 1992, Biochemistry.

[33]  A. Mazar,et al.  Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. , 1992, The Journal of biological chemistry.

[34]  E. Appella,et al.  The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. , 1987, The Journal of biological chemistry.

[35]  L. Ossowski,et al.  A proenzyme form of human urokinase. , 1982, The Journal of biological chemistry.

[36]  M. Lippman,et al.  Model systems for the study of estrogen action in tissue culture. , 1976, Journal of steroid biochemistry.

[37]  N. Brünner,et al.  The urokinase plasminogen activator system as a target for prognostic studies in breast cancer , 2004, Breast Cancer Research and Treatment.

[38]  A. Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[39]  E. Appella,et al.  The Receptor-Binding Sequence of Urokinase , 1987 .